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Since the introduction of new anti-retroviral agents and saquinavir inhibited adherence of Candida albicans
under the chosen experimental conditions similarly tosuch as human immunodeficiency virus (HIV) protease
inhibitors, oropharyngeal candidiasis is less often the in vitro results, whereas indinavir had no effect.
This inhibition was shown to be concentration depend-observed in acquired immune deficiency syndrome
patients. Secretory aspartic proteases of Candida ent. The specificity of these effects with respect to
the secretory aspartic proteases was demonstrated byalbicans, which have similarities to the HIV aspartic
proteases, are pathogenicity factors that have been competitive binding experiments using purified
recombinant secretory aspartic proteases. On the basisintensively investigated in recent years. The inhibitory
effect of four different HIV aspartic protease inhibitors of these studies we conclude that lower rates of oro-
pharyngeal candidiasis in individuals receiving potent(ritonavir, saquinavir, indinavir, and nelfinavir), on the
activity of different Candida albicans secretory aspartic anti-retroviral therapy could reflect not only an
improvement in the immune system but also directproteases was demonstrated. These anti-retroviral
agents were able to inhibit Candida albicans secretory inhibition of Candida secretory aspartic proteases by
HIV protease inhibitors. Key words: adherence/asparticaspartic proteases 1, 2, and 3 which are involved in
Candida adherence. As a consequence of these results protease inhibitors/aspartic proteases/Candida albicans/
human immunodeficiency virus inhibitors/oropharyngeal can-we used selected HIV protease inhibitors in an adher-
ence assay of Candida cells to epithelial cells. Ritonavir didiasis. J Invest Dermatol 113:747–751, 1999
O the fungus to host cells and tissues is the initial step leading to theestablishment of infection and is thus considered to be essential tovirulence (Cutler, 1991). The binding mechanisms are mediatedby complementary molecules at both the surface of the fungus andthe host. During recent years, C. albicans secreted aspartic proteasesropharyngeal candidiasis (OC) is the most commonfungal disease among patients suffering from humanimmunodeficiency virus (HIV) infection. Some80–95% of HIV-infected patients will have at leastone episode of OC during the course of their
disease and two-thirds of these patients will have OC as their initial (Sap) have attracted a lot of attention as virulence factors, and have
symptomatic illness. Candida albicans is responsible for the majority been demonstrated on the surface of fungal elements colonizing
of these infections (for review see Penzak and Gubbins, 1998). mucosa and penetrating tissues (Borg and Ru¨chel, 1988). Evidence
Since the introduction of highly active anti-retroviral therapy using for the role of Sap in the adherence process has been derived from
HIV aspartic protease inhibitors and nucleoside analogs, however, experiments with the specific inhibitor pepstatin A, which is able
HIV-associated opportunistic infections such as OC due to to block adherence of C. albicans cells (Ollert et al, 1993).
C. albicans are less often observed even in the presence of viral HIV aspartic proteases and Candida Sap are enzymes which
resistance to treatment (Egger et al, 1997; Palella et al, 1998; belong to the same class of proteases (Rao et al, 1990). Six closely
Ledergerber et al, 1999) related secreted C. albicans aspartic proteases Sap1–Sap6 have been
Candida albicans is a dimorphic fungus that is both a commensal successfully produced as recombinant proteins in the methylotrophic
and opportunistic pathogen in humans (Odds, 1988). Adhesion of yeast Pichia pastoris and well characterized (Borg-von Zepelin et al,
1998). The availability of purified recombinant Sap1–Sap6 allowed
us to test the effect of four different HIV aspartic protease inhibitors,
Manuscript received April 28, 1999; revised July 1, 1999; accepted for ritonavir, saquinavir, indinavir and nelfinavir on the C. albicans Sap
publication July 22, 1999. activity. Additionally, we tested the influence of these HIV protease
Reprint requests to: Dr. Michel Monod, Service de Dermatologie, inhibitors on the adherence of various Candida strains to epithelialLaboratoire de Mycologie, BT422, Center Hospitalier Universitaire
cells using a previously described assay (Borg-von Zepelin andVaudois, 1011 Lausanne, Switzerland. Email: Michel.Monod@chuv.
Wagner, 1995). The results of the adherence assay were correlatedhospvd.ch
to the direct effect of the HIV protease inhibitors on the differentAbbreviations: OC, oropharyngeal candidiasis; Sap, secretory aspartic
protease. Sap leading to the hypothesis that the decrease in the frequency of
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Cell culture Vero cells were cultivated in medium 1640 containing 5%Table I. Sap enzyme activities in the presence of HIV
fetal bovine serum in cell culture flasks. The preparation of the microtestaspartic protease inhibitorsa
plates for the standard adherence assay was performed as previously described
(Borg-von Zepelin and Wagner, 1995). Briefly, the detached Vero cellsInhibitor Sap1 Sap2 Sap3 Sap4 Sap5 Sap6
were suspended in new cell culture medium at a concentration of 105 cells
per ml. Each position of a flat-bottomed microtest plate was filled withRitonavir
200 µl of this Vero cell suspension. Prior to testing adherence, the Vero3.2 µM 66 46 86 100 100 100
cells were incubated in the microtest plates for 24 h at 37°C (5% CO2,16 µM 34 33 65 100 100 100
95% humidity).32 µM 25 27 49 100 100 100
Saquinavir
32 µM 78 97 87 100 100 93 Standard adherence assay This assay was essentially performed as
160 µM 53 91 86 100 100 96 previously described (Borg-von Zepelin and Wagner, 1995). Candida cells
320 µM 41 46 78 90 87 77 at the end of the logarithmic growth phase were washed twice with cold
Nelfinavir PBS. The number of cells was determined photometrically at 630 nm on
32 µM 96 81 82 100 100 95 the basis of standard curves or by hemocytometry. The yeasts were
160 µM 67 67 65 100 100 93 cultivated in 0.1 M phosphate buffer 1 50 mM glucose pH 6.0 or medium
320 µM 45 17 46 100 100 82 1640 supplemented with 5% fetal bovine serum (adherence media) at a
Indinavir concentration of 2 3 106 cells per ml. The wells of the microtest plate
32 µM 100 91 78 100 100 100 containing Vero cells were infected with 200 µl of the Candida cell
160 µM 94 46 58 100 100 100 suspension. Yeasts and target cells were incubated for at least 1 h at 37°C.
320 µM 88 39 16 100 100 100 For the detection of adherent Candida cells, the dye Calcofluor white
(stock solution 0.2 mg per ml) was directly applied to the adherence
aPercent values of enzyme activity in the presence of inhibitors. A value of 100% medium at each position (final concentration 20 µg per ml). Subsequently,
corresponds to activity in the absence of inhibitor. the plates were incubated for 30 min at 37°C. All wells of the microtest
plate were rinsed three times with PBS to remove nonadherent Candida
cells. Finally, the amount of adherent fluorescent Candida cells was
oropharyngeal candidiasis might be assisted by inhibition of Sap determined by an automatic fluorescence reader (CytoFluor II, Biosearch,
Somerville, NJ) at extinction 360 nm and emission 460 nm.involved in C. albicans adherence.
As a standard procedure, each test was performed at least four times in
MATERIALS AND METHODS parallel on the same microtest plate in order to determine mean values
and SD.
Strains The C. albicans wild-type strains SC5314, ATCC10231, 10261,
48867, CBS2730, DSM70014, and clinical isolates from the bacteriological
Adherence assay in the presence of different HIV-proteasedepartment of the university clinics of Go¨ttingen were used in this study.
inhibitors Prior to the infection of Vero cells, differing concentrationsForty-eight hours before use, the strains were plated on Sabouraud agar
of the HIV protease inhibitors were added to Candida yeast cells. Controland incubated at room temperature. For the adherence assays, the yeasts
tests without inhibitor, either containing 1% methanol as solvent forwere grown for 14 h in glucose broth at 35°C. At that time point the
ritonavir or water as solvent for saquinavir and indinavir were performedyeasts were at the end of the logarithmic growth phase.
in parallel on the same microtest plate. These controls without inhibitors
were set to 100%. The results of the adherence assay with inhibitorsProteases and protease inhibitors The different C. albicans Sap tested
were expressed as percentages of the corresponding control tests withoutwere expressed as recombinant proteins using the P. pastoris expression
inhibitors. The differences between the control tests without proteasesystem and purified as previously described (Borg-von Zepelin et al, 1998).
inhibitors and the Candida adherence in the presence of HIV proteaseProtein concentrations were measured by the method of Bradford (1976)
inhibitors was analyzed statistically using the Student’s t test.using a commercial kit (BioRad, Richmond, CA).
In order to assay the concentration-dependence of selected inhibitors,The inhibitors ritonavir (ABT 538), saquinavir (Ro 31–8959), nelfinavir
saquinavir and ritonavir were first added to the adherence medium (0.1 M(AG 1343), and indinavir (L 735,524), obtained from commercial sources,
phosphate buffer 1 50 mM glucose) beginning with a concentration ofwere prepared as follows: Indinavir and saquinavir were dissolved in Aqua
200 µM. Inhibitors concentration was then 2-fold diluted in the samebidest. at concentrations of 20 mM and 2 mM, respectively. Nelfinavir and
adherence medium in five steps. The adherence assay was performed asritonavir were dissolved in methanol at concentrations of 20 mM and
described above.40 mM, respectively. Pepstatin A was purchased from Sigma (Taufkirchen,
In order to test the reversal of adherence inhibition caused by HIVGermany), and a stock solution was prepared in methanol at a concentration
inhibitors, ritonavir and the different Sap were mixed and preincubated inof 10–2 M.
50 mM citrate buffer, pH 4 for 15 min at 37°C. This mixture was then
added to the Candida cells prior to the infection of the target cells.Effect of protease inhibitors on Sap proteolytic activity Each
compound was added at different concentrations (compare Table I) to
0.5 µg of enzyme in 0.45 ml of 50 mM sodium citrate buffer (pH 3.5– Immunofluorescence microscopy Vero cells were cultivated for 48 h
in 24-well test plates (Nunc no. 143982) containing round glass coverslips5.0 depending on the optimum pH of activity of the enzyme). The mixture
was incubated for 10 min at 37°C, and assays were performed after addition (diameter 12 mm) in cell culture medium containing 5% fetal bovine
serum. The target cells were then infected with Candida cells (2 3 106 cellsof 50 µl of a 0.2% solution of resorufin-labeled casein. An appropriate
control without inhibitor was assayed simultaneously. After a 60 min per ml) in adherence medium in the presence or in the absence of aspartic
protease inhibitors. Candida and Vero cells were incubated for at least 4 hincubation at 37°C, the undigested substrate was precipitated with trichloro-
acetic acid (4% final concentration) and separated from the supernatant by at 37°C. Following coincubation, the wells were rinsed once with PBS.
Freshly prepared paraformaldehyde (2% in PBS) was then applied andcentrifugation. The absorbance of the supernatant as a function of the Sap
activity was measured in the alkaline range at 574 nm following addition incubated for at least 1 h at room temperature.
Immunofluorescence microscopy was performed using an anti-serumof 30 µl 4 M NaOH.
(α-Sap2) raised in New Zealand White rabbits reacting with Sap1, Sap2,
and Sap3 (Borg-von Zepelin et al, 1998). The fixed specimens were rinsedCandida viability assays in the presence of HIV protease
inhibitors Candida cells at the end of the logarithmic growth phase were with PBS and subsequently incubated with PBS 1 1% bovine serum
albumin and 0.1% milk powder to reduce nonspecific binding for 1 h atwashed twice with cold phosphate-buffered saline (PBS). The number of
Candida cells was determined photometrically by hemocytometry. The room temperature. The anti-serum was applied (100-fold diluted in
PBS 1 1% bovine serum albumin 1 0.1% milk powder) and incubated atyeasts were then transferred to medium RPMI 1640 supplemented with
5% fetal bovine serum at a concentration of 2 3 106 cells per ml. The 8°C for at least 12 h. After another series of rinses with PBS a second
antibody fluorescein isothiocyanate-conjugate from goat was added (dilutedHIV protease inhibitors were added at a final concentration of 200 µM.
For comparison, control tests without inhibitors containing the solvents 200-fold in the above-mentioned buffer). After 3 h incubation and five
subsequent rinses in PBS, the tests were embedded in p-phenylenediamineonly, were incubated in parallel. The cell concentrations in the presence
and in the absence of HIV protease inhibitors were measured by hemocyto- according to Johnson et al (1982). The binding of the conjugate was
evaluated with a Zeiss fluorescence microscope using the filter combination,metry after 2, 4, 6, 8, and 24 h of cultivation at 37°C (5% CO2,
95% humidity). BP 450–490/FT 510/LP 520.
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Figure 2. Concentration-dependent adherence of C. albicans SC5314
by the HIV-protease inhibitors ritonavir and saquinavir in 0.1 M
phosphate buffer, pH 6.0 plus 50 mM glucose. Adherence values (A%)Figure 1. Adherence of C. albicans SC5314 to Vero cells using HIV
are a percentage of the results of the control adherence assays without HIVprotease inhibitors. Adherence assay performed using in phosphate-
protease inhibitors, which are set to 100%. The mean 6 maximal SD isbuffered (0.1 M, pH 6.0) glucose (50 mM) adherence medium. In the
depicted. The SD varied between 6% and 15%.assay the HIV protease inhibitors were used at final concentrations of
200 µM. Adherence values are a percentage of the control tests without
inhibitor (100%). The mean 6 maximal SD is depicted. The SD varied
between 9% and 13%. Figure 3 demonstrates that in the presence of ritonavir, only few
Candida cells are adherent. Compared with control tests without
the HIV protease inhibitor it is additionally obvious that these fewRESULTS
adherent Candida cells produce shorter germination tubes (Fig 3a,
Effect of HIV protease inhibitors on Sap proteolytic activity b). The presence of protease antigen on the fungal surfaces was
in vitro Depending on the Sap isoenzyme produced, a yield of demonstrated by the binding of the antibody α-Sap2, which
20–80 µg of protein per ml of P. pastoris culture supernatant was recognizes the protease antigens of Sap1, Sap2, and Sap3 (Borg-
obtained. Saquinavir, ritonavir, nelfinavir, and indinavir were tested von Zepelin et al, 1998). There were no obvious differences
at concentrations in the range of 3.2–320 µM (Table I). Sap1, Sap2, between the Candida cells grown with or without the HIV protease
and Sap3 were inhibited by all four inhibitors in a concentration- inhibitor (Fig 3c, d).
dependent manner. Ritonavir was by far the most effective inhibitor. The HIV protease inhibitors did not affect Candida viability.
Under our experimental conditions, a 50% inhibition was obtained Compared with Candida cells cultured without HIV protease
with 3.2–32 µM of ritonavir, which are concentrations comparable inhibitors, neither differences in cell concentrations nor differences
with those achievable in patients (Hsu et al, 1997). Ten-fold higher in growth kinetics were observed in the presence of the HIV
concentrations of saquinavir, nelfinavir, and indinavir were necessary protease inhibitors ritonavir and saquinavir at various time points
to obtain similar inhibition of Sap1, Sap2, and Sap3. In contrast, of the cultivation (data not shown).
only a slight inhibition of activity was detected for Sap4, Sap5, and The specificity of the adherence inhibition due to Candida Sap
Sap6 with a concentration of up to 320 µM saquinavir. was concluded from competitive binding experiments of HIV
protease inhibitors with recombinant Sap as shown in Fig 4.Effect of HIV protease inhibitors on Candida adherence
Ritonavir and Sap1, Sap2, and Sap3 were mixed and preincubatedC. albicans SC5314 was used in an adherence assay to test the effect
in 50 mM citrate buffer pH 4 for 15 min at 37°C. This mixtureof ritonavir, which most effectively inhibited Sap activities in vitro,
was then added to the Candida cells prior to the infection of theas well as saquinavir and indinavir. C. albicans adherence without
target cells. As controls, ritonavir was mixed with serum proteinsinhibitor was arbitrarily set at 100%. Under the chosen experimental
as well as bovine serum albumin (5 and 10 µg per ml) under theconditions, the addition of pepstatin A at a concentration of 100 µM
same experimental conditions. The addition of the different Sap towas used as a positive control and revealed an adherence inhibition
ritonavir completely abolished the inhibition of Candida adherence,of 30%, which is in agreement with previously published results
whereas unspecific serum proteins had no effect.(Ollert et al, 1993).
The effects of the HIV-protease inhibitors saquinavir and ritonavirUsing phosphate buffer pH 6.0 as the adherence medium, the
at a concentration of 200 µM were demonstrated with eight furtherinfluence of the HIV protease inhibitors on the adherence of
C. albicans strains from different origins. As the control, the wild-C. albicans SC 5314 was shown to differ (Fig 1). Saquinavir and
type strain C. albicans SC5314 was tested in parallel. The comparisonritonavir used at concentrations of 200 µM revealed a marked
of these Candida strains in the presence and in the absence of theinhibition of the adherence. The addition of ritonavir and saquinavir
HIV protease inhibitors is shown in Fig 5. The addition of ritonavirreduced the adherence of C. albicans SC5314 to 30% and 50% of
reduced adherence in the same strains by 40–60% compared withthe controls, respectively, at the end of the adherence period. The
the controls without inhibitor. For all strains, the addition ofdifferences in adherence between C. albicans SC5314 without
saquinavir was less effective with only a 20–40% reduction inprotease inhibitors and in the presence of each inhibitor at a
adherence.concentration of 200 µM was found to be highly significant
(p , 0.001). In contrast, indinavir did not influence the adherence DISCUSSIONof C. albicans cells under the chosen experimental conditions
(Fig 1). The inhibition measured in the presence of ritonavir and Secretory proteases from C. albicans have attracted great interest as
defined virulence factors. Nine genes encoding Sap have beensaquinavir was found to be concentration dependent (Fig 2).
Whereas ritonavir still distinctly inhibited the adherence of cloned from C. albicans to date (Monod et al, 1994, 1998). Sap1,
Sap2, and Sap3 as well as Sap4, Sap5, and Sap6 form 2 subgroupsC. albicans SC5314 up to a concentration of 25 µM, the end-point
of adherence-inhibition caused by saquinavir was only clearly seen each containing closely related enzymes, whereas Sap7, Sap8, and
Sap9 do not form a specific group. The fact that C. albicans inhabitat a 4-fold higher concentration only (100 µM, Fig 2).
The inhibition of adherence in the presence of HIV protease diverse host niches leads to the question of whether different Sap
are expressed by C. albicans as a reaction to specific adaptationinhibitors was also visualized by immunofluorescence microscopy.
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Figure 3. Fluorescence micrograph of C. albicans SC5314 after adherence on Vero cells in the absence (a, c) and in the presence (b, d) of
200 mM ritonavir. The cells were stained with Calcofluor white under the same conditions as used in the adherence assay (a, b). Scale bar: 10 µm.
Immunoreaction with antibody α-Sap2, recognizing Sap1, Sap2, and Sap3 on the fungal surface (c, d). No obvious differences are observed. Scale bar: 20 µm
Figure 5. Adherence of nine different C. albicans strains supple-
mented by ritonavir and saquinavir (200 mM). Adherence values (A%)
Figure 4. Competitive binding experiments using recombinant Sap are a percentage of the results of the control adherence assays of the same
with the inhibitory effect on the Candida adherence caused by Candida strains without inhibitor (100%). The SD varied between 4%
ritonavir. Prior to the addition to the Candida cells, ritonavir was mixed and 15%.
with Sap1, Sap2, and Sap3 at a concentration of 2 µg per ml each and
incubated for 15 min at 37°C. Control experiments were performed in
the presence of unspecific proteins (10 µg per ml). The SD varied between and Sap3 appear to be the Sap produced during mucosal adherence.
10% and 17%. In contrast, Sap4, Sap5, and Sap6 have been shown to be secreted
in macrophages after phagocytosis of yeast cells (Borg-von Zepelin
et al, 1998). In these studies we have demonstrated that the Saprequirements under different environmental conditions. The first
studies concerned with such problems were carried out on the involved in adherence, Sap1, Sap2, and Sap3, are those inhibited
by HIV protease inhibitors.basis of gene expression. With the help of reverse transcription–
polymerase chain reaction the expression of genes SAP1, SAP2, We, therefore, tried selected anti-retroviral substances in a
previously described adherence assay (Borg-von Zepelin andSAP3, and SAP6 was demonstrated in samples of experimental and
clinical candidosis (Schaller et al, 1998). The expression of SAP1 Wagner, 1995) to address possible inhibition of the adherence of
C. albicans cells to the Vero target cells by HIV protease inhibitors.and SAP2 was also shown by northern blot analysis using an
experimental rat vaginitis model (De Bernardis et al, 1995). In Epithelial cells were used as a model for mucosal infections instead
of keratinocytic cells, e.g., HaCat line or keratinocytes obtainedparticular, Sap2 seemed to have a certain potential importance for
the vaginal infection as was deduced from infection assays using from human foreskins which could be used as a model for
skin infections. The inhibition of adherence was not caused byprotease-deficient mutant strains in the rat model (De Bernardis
et al, 1999). From these data it must be concluded that Sap1, Sap2, diminishing the viability of the Candida cells (Diz et al, 1999).
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Ritonavir, which is the most active inhibitor of Sap activity in vitro,
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